title: Therapeutic Effect of Obestatin in the Course of Cerulein-Induced Acute Pancreatitis.
abstract: OBJECTIVE
  The aim of this study was to determine the impact of obestatin therapy on the course of cerulein-induced pancreatitis.
  
  
  METHODS
  Acute pancreatitis was induced by cerulein given intraperitoneally 5 times with 1 hour intervals at the dose of 50 μg/kg per dose. Obestatin was administered twice a day at the dose of 8 nmol/kg per dose, starting the first dose 24 hours after the last injection of cerulein. Severity of acute pancreatitis (AP) was examined at 0 hour or 1, 2, 3, 5, 7, and 10 days after the last injection of cerulein.
  
  
  RESULTS
  Administration of cerulein led to development of acute edematous pancreatitis in all rats, and maximal severity of this disease was observed 24 hours after induction of pancreatitis. Treatment with obestatin reduced morphological signs of pancreatic damage (pancreatic edema, leukocyte infiltration, vacuolization of acinar cells) and led to earlier regeneration of the pancreas. Biochemical indexes of severity of pancreatitis such as serum activity of pancreatic digestive enzymes were significantly reduced in animals treated with obestatin. These effects were accompanied by increase in pancreatic DNA synthesis and decrease in serum level of proinflammatory interleukin 1β. In addition, administration of obestatin improved pancreatic blood flow in rats with AP.
  
  
  CONCLUSIONS
  Treatment with exogenous obestatin reduces severity of AP and accelerates pancreatic recovery.
authors.affiliation: From the *Department of Endocrinology and Diabetes Mellitus, Northumbria NHS Foundation Trust, North Shields, Tyne and Wear, United Kingdom; Departments of †Physiology, ‡Clinical Biochemistry, and §Pathology, Jagiellonian University Medical College, Krakow, Poland.
authors.forename: Jakub
authors.initials: J
authors.lastname: Bukowczan
authors.forename: Jakub
authors.initials: J
authors.lastname: Cieszkowski
authors.forename: Zygmunt
authors.initials: Z
authors.lastname: Warzecha
authors.forename: Piotr
authors.initials: P
authors.lastname: Ceranowicz
authors.forename: Beata
authors.initials: B
authors.lastname: Kusnierz-Cabala
authors.forename: Romana
authors.initials: R
authors.lastname: Tomaszewska
authors.forename: Artur
authors.initials: A
authors.lastname: Dembinski
mesh_terms: D000208:Acute Disease; D000818:Animals; D002108:Ceruletide; D004247:DNA / Q000096:biosynthesis / Q000235:genetics; D004334:Drug Administration Schedule; D054439:Ghrelin / Q000008:administration & dosage / Q000494:pharmacology*; D053583:Interleukin-1beta / Q000097:blood; D008297:Male; D010179:Pancreas / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics; D017208:Rats, Wistar; D012038:Regeneration / Q000187:drug effects*; D012039:Regional Blood Flow / Q000187:drug effects; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D054439:Ghrelin; D053583:Interleukin-1beta; D002108:Ceruletide; D004247:DNA